肝硬化合并肝癌及单纯肝癌患者免疫功能检测结果分析

doi:10.3969/j.issn.1673-8640.2014.11.012

检验医学 ›› 2014, Vol. 29 ›› Issue (11): 1128-1131.DOI: 10.3969/j.issn.1673-8640.2014.11.012

肝硬化合并肝癌及单纯肝癌患者免疫功能检测结果分析

张一超¹，夏骏²，李雄³

1.临安市人民医院检验科,浙江临安 311300；
2.浙江省人民医院检验科,浙江杭州 310014；
3杭州艾迪康医学检验中心实验室,浙江杭州 310023

收稿日期:2014-07-22 出版日期:2014-11-01 发布日期:2014-11-28
作者简介:张一超，男，1983生，学士，主管技师，主要从事临床免疫学检验工作。

The detection result analysis on the immune functions in cirrhosis patients with liver cancer and patients with liver cancer alone

ZHANG Yichao¹, XIA Jun², LI Xiong³

1. Department of Clinical Laboratory, Lin'an People's Hospital, Zhejiang Lin'an 311300, China;
2. Department of Clinical Laboratory, Zhejiang People's Hospital, Zhejiang Hangzhou 310014, China;
3. Central Laboratory, Hangzhou ADICON Clinical Laboratories, Zhejiang Hangzhou 310023, China

Received:2014-07-22 Online:2014-11-01 Published:2014-11-28

摘要/Abstract

摘要：

目的　探讨肝硬化合并肝癌患者及单纯肝癌患者细胞免疫及体液免疫功能的变化情况。方法　选取肝硬化合并肝癌及单纯肝癌患者各40例，同期无肝病诊断史的健康人40名为对照。分别抽取对照者及肝癌患者外周血，以流式细胞术检测细胞免疫水平变化:T淋巴细胞亚群（CD3、CD4、CD8、CD4/CD8）的值；免疫透射比浊法检测体液免疫（IgA、IgG、IgM）的浓度。结果　与对照组相比，两组肝癌患者CD3、CD4、CD4/CD8比值明显降低（P均＜0.05），而肝硬化合并肝癌CD3、CD4 、CD4/CD8比值与单纯肝癌患者相比明显下降（P均＜0.05）。与对照组相比，两组肝癌患者IgA、IgG、IgM明显上升，而肝硬化合并肝癌较单纯肝癌患者lgA、lgG、lgM值上升更为明显（P均＜0.05）。结论　肝硬化合并肝癌患者免疫功能下降较单纯肝癌患者下降更为明显。因此，改善肝癌患者机体免疫功能，重建机体防御系统是很重要的治疗措施，同时监测机体免疫功能的改变，对估计预后、指导临床治疗有积极作用。

关键词: 肝癌, 肝硬化, 细胞免疫, 体液免疫

Abstract:

Objective　To investigate the changes of cellular and humoral immune functions in cirrhosis patients with liver cancer and patients with liver cancer alone. Methods　A total of 40 cirrhosis patients with liver cancer and 40 patients with liver cancer alone were enrolled. At the same period， 40 healthy subjects with no liver disease history were enrolled as controls. Their peripheral blood samples were extracted， and their cellular immune level changes were determined by flow cytometry， including T lymphocyte subset（CD3， CD4， CD8 and CD4 / CD8） values. The concentrations of humoral immunity（IgA， IgG and IgM） were determined by immunoturbidimetry. Results　The CD3， CD4 and CD4/CD8 significantly decreased in liver cancer patients than in controls（P＜0.05）， and the CD3， CD4 and CD4/CD8 in cirrhosis patients with liver cancer decreased obviously compared with those in patients with liver cancer alone（P＜0.05）. Compared with those in controls， the IgA， IgG and IgM increased obviously in liver cancer patients， and the IgA， lgG and lgM increased obviously in cirrhosis patients with liver cancer compared with those in patients with liver cancer alone（P＜0.05）. Conclusions　The immune functions of cirrhosis patients with liver cancer decrease more significantly than those of patients with liver cancer alone. Therefore， improving the immune functions in patients with liver cancer and rebuilding the defense system are so important， and monitoring the changes of immune functions has a positive role for estimating prognosis and guiding clinical treatment.

Key words: Liver cancer, Cirrhosis, Cellular immunity, Humoral immunity

中图分类号:

R446.11

张一超，夏骏，李雄. 肝硬化合并肝癌及单纯肝癌患者免疫功能检测结果分析[J]. 检验医学, 2014, 29(11): 1128-1131.

ZHANG Yichao, XIA Jun, LI Xiong. The detection result analysis on the immune functions in cirrhosis patients with liver cancer and patients with liver cancer alone[J]. , 2014, 29(11): 1128-1131.

参考文献

[1] Guglielmi A, Ruzzenente A, Conci S, et al.Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations[J]. World J Gastroenterol, 2014, 20(24):7525-7533.
[2] Hato T, Goyal L, Greten TF, et al. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions[J]. Hepatology, 2014. [Epub ahead of print]
[3] 王坤,房萌,赵琳,等. 肝硬化及原发性肝癌患者血清半胱氨酸蛋白酶抑制剂C水平的改变及其意义[J].检验医学, 2012, 27(2):118-121.
[4] Yan J, Liu XL, Xiao G, et al. Prevalence and clinical relevance of T-helper cells, Th17 and Th1, in hepatitis B virus-related hepatocellular carcinoma[J]. PLoS One, 2014, 9(5):e96080.
[5] Hutcheson J, Bourgo RJ, Balaji U, et al. Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma[J]. Hepatology, 2014, 60(4): 1231-1240.
[6] Guo CL, Yang XH, Cheng W, et al. Expression of Fas/FasL in CD8+ T and CD3+ Foxp3+ Treg cells relationship with apoptosis of circulating CD8+ T cells in hepatocellular carcinoma patients[J]. Asian Pac J Cancer Prev, 2014,15 (6):2613-2618.
[7] Wu J, Zou H, Jiang JT, et al.Clinical application of serum alpha-fetoprotein-IgM complexes on the diagnosis of primary hepatocellular carcinoma in Kazakh and Han populations[J]. Tumori, 2013, 99(4):535-539.
[8] Arahata M, Tajiri K, Nomoto K, et al. A novel type of selec-tive immunoglobulin m deficiency in a patient with autoimmune liver cirrhosis with recurrent hepatocellular carcinoma: a case report and review of the literature[J]. Int Arch Allergy Immunol, 2013,161(1):91-6.
[9] Ai J, Tang Q, Wu Y, et al. The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma[J]. J Natl Cancer Inst, 2011, 103(22):1696-1712.
[10] Wang M, Wang H, Tang Y, et al. Effective inhibition of a Strongylocentrotus nudus eggs polysaccharide against hepatocellular carcinoma is mediated via immunoregulation in vivo[J]. Immunol Lett, 2011, 141(1):74-82.

[1]	卫明珠, 潘继文, 罗锐, 陈俊辉. 凝血4项和肿瘤标志物对乙型肝炎相关肝癌的辅助诊断价值[J]. 检验医学, 2023, 38(9): 901-904.
[2]	中国康复医学会医学检验与康复专业委员会, 上海市医学会分子诊断专科分会, 上海市免疫学会肿瘤免疫分会, 上海中医药大学附属岳阳中西医结合医院, 上海市临床检验中心, 中国中西医结合学会检验医学专业委员会, 上海市抗癌协会检验医学专业委员会, 上海市抗癌协会肿瘤标志物专业委员会. 肝癌三项（AFP、AFP-L3%、DCP）与GALAD、类GALAD模型临床应用专家共识[J]. 检验医学, 2023, 38(7): 607-623.
[3]	陈文举, 周勇, 徐佳佳, 王攀. 血清外泌体miR-23b-3p和miR-4429诊断HCC的价值[J]. 检验医学, 2023, 38(7): 624-628.
[4]	顾怡, 王蕊, 邓杰, 杨易静, 周王柯, 陈予诺, 陈小松, 沈薇, 周景艺. 重症肝炎和肝硬化患者肝移植前后生物标志物水平差异及其预后评估价值[J]. 检验医学, 2023, 38(11): 1044-1051.
[5]	冀叶, 袁小笋, 张蕾, 马慧利, 薛永飞, 李长生, 张敬伟, 任中海, 张腾飞. lncRNA HULC在乳头状甲状腺癌组织中的表达及意义[J]. 检验医学, 2022, 37(7): 605-609.
[6]	吴苏君, 冀恒涛, 彭梦乐. IL-18、IL-37、NLRP3及NK/DC比值在乙型肝炎相关肝硬化中的临床价值[J]. 检验医学, 2022, 37(6): 518-523.
[7]	李丹, 何兵, 王梦龙, 徐瑶, 万军. 传染性单核细胞增多症合并肺炎支原体感染患儿实验室检测结果分析[J]. 检验医学, 2022, 37(2): 159-161.
[8]	孟俊, 王俊青, 费晓春, 顾志冬. 血浆外泌体circRNA诊断HCC联合检测模型的建立与验证[J]. 检验医学, 2022, 37(1): 1-10.
[9]	胡涛, 卢仁泉, 郭林. TK1检测在HCC辅助诊断及预后评估中的临床价值[J]. 检验医学, 2021, 36(9): 914-919.
[10]	包大伟, 黄建. CD133和ALDH1在肝细胞肝癌中的临床价值[J]. 检验医学, 2021, 36(9): 925-928.
[11]	卢佩, 丁振若, 郑善銮, 刘海波. 尿液中红细胞免疫球的检测及其临床意义[J]. 检验医学, 2021, 36(9): 932-934.
[12]	程惠芬. 血清P-选择素、ICAM-1、IL-17A水平在HBV感染相关疾病中的临床价值[J]. 检验医学, 2021, 36(6): 646-649.
[13]	刘婷婷, 林玉婷, 米拉, 李晓勤. 血清IL-33水平及其基因多态性与HBV感染临床转归的相关性[J]. 检验医学, 2021, 36(11): 1101-1105.
[14]	曾建涛, 李泉, 周丽莉, 董姗姗, 郑兆斌. SARS-CoV-2、HCoV-OC43和HCoV-HKU1棘突蛋白抗原表位分析[J]. 检验医学, 2020, 35(9): 933-936.
[15]	童林, 黄晨军, 高致远, 周军, 房萌, 肖潇, 何羽童, 洪松, 许敏凡, 朱飞飞, 高春芳. 基于临床常用检验项目的原发性肝细胞肝癌术前微血管侵犯诊断模型研究[J]. 检验医学, 2020, 35(8): 741-748.

肝硬化合并肝癌及单纯肝癌患者免疫功能检测结果分析

The detection result analysis on the immune functions in cirrhosis patients with liver cancer and patients with liver cancer alone

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics